Real-world evidence in NSCLC asset development: Global trials, treatment patterns, and predictive models
Explore how longitudinal real-world data informs treatment sequencing, trial design, and clinical prediction in non-small cell lung cancer.
Asset development decisions often rely on assumptions about patients and their treatment: which regimens they receive, in what order, and whether they were tested at all. With more of the oncology pipeline starting in China, trial results may not reflect U.S. patients or practice.
In this virtual webinar, Tempus will explore testing, treatment, and development patterns in NSCLC. The session will include several real-world applications relevant to today’s research, including:
Evaluating lines of therapy in EGFR-mutant NSCLC post-osimertinib
Evaluating control arms for China-only trial results using RWD from U.S. patients
Expanding targeted therapies into the adjuvant/resectable setting
Leveraging foundation models to predict clinical outcomes
Conference
